skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Determining thyroid {sup 131}I effective half-life for the treatment planning of Graves' disease

Abstract

Purpose: Thyroid {sup 131}I effective half-life (T{sub eff}) is an essential parameter in patient therapy when accurate radiation dose is desirable for producing an intended therapeutic outcome. Multiple {sup 131}I uptake measurements and resources from patients themselves and from nuclear medicine facilities are requisites for determining T{sub eff}, these being limiting factors when implementing the treatment planning of Graves' disease (GD) in radionuclide therapy. With the aim of optimizing this process, this study presents a practical, propitious, and accurate method of determining T{sub eff} for dosimetric purposes. Methods: A total of 50 patients with GD were included in this prospective study. Thyroidal {sup 131}I uptake was measured at 2-h, 6-h, 24-h, 48-h, 96-h, and 220-h postradioiodine administration. T{sub eff} was calculated by considering sets of two measured points (24-48-h, 24-96-h, and 24-220-h), sets of three (24-48-96-h, 24-48-220-h, and 24-96-220-h), and sets of four (24-48-96-220-h). Results: When considering all the measured points, the representative T{sub eff} for all the patients was 6.95 ({+-}0.81) days, whereas when using such sets of points as (24-220-h), (24-96-220-h), and (24-48-220-h), this was 6.85 ({+-}0.81), 6.90 ({+-}0.81), and 6.95 ({+-}0.81) days, respectively. According to the mean deviations 2.2 ({+-}2.4)%, 2.1 ({+-}2.0)%, and 0.04 ({+-}0.09)% found inmore » T{sub eff}, calculated based on all the measured points in time, and with methods using the (24-220-h), (24-48-220-h), and (24-96-220-h) sets, respectively, no meaningful statistical difference was noted among the three methods (p > 0.500, t test). Conclusions: T{sub eff} obtained from only two thyroid {sup 131}I uptakes measured at 24-h and 220-h, besides proving to be sufficient, accurate enough, and easily applicable, attributes additional major cost-benefits for patients, and facilitates the application of the method for dosimetric purposes in the treatment planning of Graves' disease.« less

Authors:
; ; ;  [1];  [2]
  1. Cancer Institute of Sao Paulo State (ICESP), Clinical Hospital, School of Medicine, University of Sao Paulo, Sao Paulo 01246-000 (Brazil)
  2. Unit of Medical Physics, Azienda Ospedaliero-Universitaria Pisana, Pisa 56126 (Italy)
Publication Date:
OSTI Identifier:
22130536
Resource Type:
Journal Article
Journal Name:
Medical Physics
Additional Journal Information:
Journal Volume: 40; Journal Issue: 2; Other Information: (c) 2013 American Association of Physicists in Medicine; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0094-2405
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; 61 RADIATION PROTECTION AND DOSIMETRY; 60 APPLIED LIFE SCIENCES; BRACHYTHERAPY; DISEASES; DOSIMETRY; IODINE 131; OPTIMIZATION; PATIENTS; RADIATION DOSES; RESOURCES; THYROID; UPTAKE

Citation Formats

Willegaignon, Jose, Sapienza, Marcelo T., Barberio Coura Filho, George, Buchpiguel, Carlos A., Nuclear Medicine Service, Department of Radiology, School of Medicine, University of Sao Paulo, Sao Paulo 01246-000, and Traino, Antonio C. Determining thyroid {sup 131}I effective half-life for the treatment planning of Graves' disease. United States: N. p., 2013. Web. doi:10.1118/1.4788660.
Willegaignon, Jose, Sapienza, Marcelo T., Barberio Coura Filho, George, Buchpiguel, Carlos A., Nuclear Medicine Service, Department of Radiology, School of Medicine, University of Sao Paulo, Sao Paulo 01246-000, & Traino, Antonio C. Determining thyroid {sup 131}I effective half-life for the treatment planning of Graves' disease. United States. https://doi.org/10.1118/1.4788660
Willegaignon, Jose, Sapienza, Marcelo T., Barberio Coura Filho, George, Buchpiguel, Carlos A., Nuclear Medicine Service, Department of Radiology, School of Medicine, University of Sao Paulo, Sao Paulo 01246-000, and Traino, Antonio C. 2013. "Determining thyroid {sup 131}I effective half-life for the treatment planning of Graves' disease". United States. https://doi.org/10.1118/1.4788660.
@article{osti_22130536,
title = {Determining thyroid {sup 131}I effective half-life for the treatment planning of Graves' disease},
author = {Willegaignon, Jose and Sapienza, Marcelo T. and Barberio Coura Filho, George and Buchpiguel, Carlos A. and Nuclear Medicine Service, Department of Radiology, School of Medicine, University of Sao Paulo, Sao Paulo 01246-000 and Traino, Antonio C.},
abstractNote = {Purpose: Thyroid {sup 131}I effective half-life (T{sub eff}) is an essential parameter in patient therapy when accurate radiation dose is desirable for producing an intended therapeutic outcome. Multiple {sup 131}I uptake measurements and resources from patients themselves and from nuclear medicine facilities are requisites for determining T{sub eff}, these being limiting factors when implementing the treatment planning of Graves' disease (GD) in radionuclide therapy. With the aim of optimizing this process, this study presents a practical, propitious, and accurate method of determining T{sub eff} for dosimetric purposes. Methods: A total of 50 patients with GD were included in this prospective study. Thyroidal {sup 131}I uptake was measured at 2-h, 6-h, 24-h, 48-h, 96-h, and 220-h postradioiodine administration. T{sub eff} was calculated by considering sets of two measured points (24-48-h, 24-96-h, and 24-220-h), sets of three (24-48-96-h, 24-48-220-h, and 24-96-220-h), and sets of four (24-48-96-220-h). Results: When considering all the measured points, the representative T{sub eff} for all the patients was 6.95 ({+-}0.81) days, whereas when using such sets of points as (24-220-h), (24-96-220-h), and (24-48-220-h), this was 6.85 ({+-}0.81), 6.90 ({+-}0.81), and 6.95 ({+-}0.81) days, respectively. According to the mean deviations 2.2 ({+-}2.4)%, 2.1 ({+-}2.0)%, and 0.04 ({+-}0.09)% found in T{sub eff}, calculated based on all the measured points in time, and with methods using the (24-220-h), (24-48-220-h), and (24-96-220-h) sets, respectively, no meaningful statistical difference was noted among the three methods (p > 0.500, t test). Conclusions: T{sub eff} obtained from only two thyroid {sup 131}I uptakes measured at 24-h and 220-h, besides proving to be sufficient, accurate enough, and easily applicable, attributes additional major cost-benefits for patients, and facilitates the application of the method for dosimetric purposes in the treatment planning of Graves' disease.},
doi = {10.1118/1.4788660},
url = {https://www.osti.gov/biblio/22130536}, journal = {Medical Physics},
issn = {0094-2405},
number = 2,
volume = 40,
place = {United States},
year = {Fri Feb 15 00:00:00 EST 2013},
month = {Fri Feb 15 00:00:00 EST 2013}
}